Revvity (NYSE:RVTY) Stock Unloaded by Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Revvity Inc. (NYSE:RVTY). In a filing disclosed on November 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Revvity stock on October 27th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 11/2/2026.
• Purchased $1,001 – $15,000 in shares of argenex (NASDAQ:ARGX) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Illumina (NASDAQ:ILMN) on 10/27/2026.
• Sold $15,001 – $50,000 in shares of PTC (NASDAQ:PTC) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Micron Solutions (OTCMKTS:MICR) on 10/21/2026.
• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of Moderna (NASDAQ:MRNA) on 10/20/2026.

Revvity Stock Down 0.7%

Revvity stock traded down $1.14 during midday trading on Thursday, hitting $157.11. The stock had a trading volume of 1,467,522 shares, compared to its average volume of 1,892,040. The business has a fifty day moving average price of $150.01 and a 200 day moving average price of $114.10. Revvity Inc. has a 12 month low of $81.22 and a 12 month high of $171.74. The stock has a market cap of $17.54 billion, a P/E ratio of 28.51, a P/E/G ratio of 2.77 and a beta of 1.08. The company has a current ratio of 2.65, a quick ratio of 2.10 and a debt-to-equity ratio of 0.36.

Revvity (NYSE:RVTY) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported $1.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.30 by $0.08. The business had revenue of $728.90 million for the quarter, compared to analyst estimates of $694.73 million. Revvity had a return on equity of 8.64% and a net margin of 8.61%. The business’s revenue was up 4.3% compared to the same quarter last year. During the same period in the prior year, the company posted $1.18 EPS. Research analysts predict that Revvity Inc. will post 5.42 EPS for the current year.

Revvity Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 12th. Investors of record on Friday, January 22nd will be issued a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.2%. The ex-dividend date of this dividend is Friday, January 22nd. Revvity’s payout ratio is currently 12.39%.

Insider Activity

In other Revvity news, insider Maxwell Krakowiak sold 1,631 shares of the stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $144.53, for a total transaction of $235,728.43. Following the sale, the insider owned 14,781 shares of the company’s stock, valued at $2,136,297.93. This represents a 9.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Tajinder Vohra sold 7,330 shares of the firm’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $140.88, for a total transaction of $1,032,650.40. Following the completion of the sale, the insider owned 6,635 shares of the company’s stock, valued at $934,738.80. The trade was a 52.49% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 9,045 shares of company stock worth $1,281,439. 0.85% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages recently weighed in on RVTY. JPMorgan Chase & Co. lifted their price objective on shares of Revvity from $155.00 to $160.00 and gave the company a “neutral” rating in a research report on Wednesday, November 4th. Bank of America restated a “neutral” rating on shares of Revvity in a research report on Wednesday, November 4th. UBS Group assumed coverage on shares of Revvity in a research note on Wednesday, September 9th. They issued a “neutral” rating and a $140.00 price target on the stock. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Revvity in a report on Thursday. Finally, Zacks Research upgraded Revvity from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 4th. Six equities research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company. According to data from MarketBeat.com, Revvity currently has an average rating of “Hold” and an average target price of $133.86.

Institutional Investors Weigh In On Revvity

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Apollon Wealth Management LLC raised its position in shares of Revvity by 2.7% during the third quarter. Apollon Wealth Management LLC now owns 2,778 shares of the company’s stock valued at $425,000 after buying an additional 73 shares during the last quarter. Moors & Cabot Inc. increased its stake in shares of Revvity by 3.1% in the third quarter. Moors & Cabot Inc. now owns 2,448 shares of the company’s stock valued at $374,000 after buying an additional 73 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Revvity by 5.4% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,074 shares of the company’s stock valued at $231,000 after buying an additional 106 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of Revvity by 17.0% in the first quarter. EverSource Wealth Advisors LLC now owns 749 shares of the company’s stock valued at $66,000 after buying an additional 109 shares during the last quarter. Finally, Angeles Wealth Management LLC raised its holdings in shares of Revvity by 2.0% in the second quarter. Angeles Wealth Management LLC now owns 5,804 shares of the company’s stock valued at $646,000 after buying an additional 112 shares during the last quarter. Hedge funds and other institutional investors own 86.65% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Revvity

Revvity, Inc. develops and supplies products and services for life sciences research and clinical diagnostics. Its offerings include instruments, reagents, software and related services used by pharmaceutical and biotechnology companies, academic and government research institutions, hospitals and clinical laboratories. The company’s work spans areas such as drug discovery and development, genetic testing, newborn screening and other diagnostic applications. Its technologies help researchers and healthcare providers analyze biological samples and generate information used in research and patient care.